Stock listing

UTHR Stock Price, News, Filings & Events — United Therapeutics Corporation

Selected listing: UTHR · NASDAQ · USD · US

This page tracks United Therapeutics Corporation's UTHR:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following UTHR:NASDAQ. UTHR:NASDAQ is the stock-level entry point for investors researching United Therapeutics Corporation, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. United Therapeutics Corporation, traded under the ticker UTHR, is a public company based in the United States with a market capitalization of approximately $22.43 billion. The company focuses on innovative therapies for the treatment of chronic and life-threatening conditions. United Therapeutics is committed to advancing healthcare solutions and improving patient outcomes through its research and development...

UTHR:NASDAQUSDUSUpdated August 31, 2026

Ticker: UTHR:NASDAQ
Asset type: Stock
Market cap: $22.11B
Sector: Health Technology
Industry: Biotechnology
Exchange: NASDAQ
Currency: USD

United Therapeutics Corporation UTHR:NASDAQ stock context

Latest news from United Therapeutics Corporation

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

September 1, 2026

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International ...

August 28, 2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hyperte...

August 24, 2026

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

August 5, 2026

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across met...

July 31, 2026

All United Therapeutics Corporation news →

United Therapeutics Corporation earnings calls

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call

August 5, 2026 · Replay with transcript and chapters

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call

May 6, 2026 · Replay with transcript and chapters

United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call

February 25, 2026 · Replay with transcript and chapters

United Therapeutics Corporation (UTHR) Q3 2025 Earnings Call

October 29, 2025 · Replay with transcript and chapters

United Therapeutics Corporation (UTHR) Q2 2025 Earnings Call

July 30, 2025 · Replay with transcript and chapters

United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call

April 30, 2025 · Replay with transcript and chapters

Research United Therapeutics Corporation

United Therapeutics Corporation investor report

Review AI stock analysis and investor report context for UTHR:NASDAQ.

United Therapeutics Corporation company profile

View the public company page for United Therapeutics Corporation on 6ix.

United Therapeutics Corporation news

Read company news and market updates connected to United Therapeutics Corporation.

United Therapeutics Corporation investor events

Find investor webinars, events, and replay context for United Therapeutics Corporation.